Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, specifically for pharmaceutical manufacturing and pharmaceutical services [1][2]. Core Insights - Continuous attention is recommended for innovative drugs with rising prosperity, as evidenced by the record number of 73 oral reports on Chinese innovative drug assets at the 2025 ASCO annual meeting [2][36]. - The Chinese innovative drug sector is experiencing a significant demand from multinational corporations (MNCs), which is reflected in the increasing number of overseas business development (BD) transactions [36]. - The pharmaceutical sector outperformed the market in May 2025, with the SW Pharmaceutical and Biological sector rising by 6.4%, ranking first among Shenwan's primary industries [15][37]. Summary by Sections Investment Highlights - The report highlights a portfolio of A-Shares including Jiangsu Heng Rui Medicine, Huadong Medicine, Sichuan Kelun Pharmaceutical, and others, indicating a focus on companies with strong growth potential [2][5]. - The report notes that the pharmaceutical sector's premium level relative to all A-Shares is currently at a normal level, with a relative premium rate of 87.88% as of the end of May 2025 [28][37]. Performance Analysis - In May 2025, the pharmaceutical sector's performance was ranked first, with individual stock gains led by Staidson Beijing BioPharmaceuticals (+145.4%) and Sunshine Guojian Pharmaceutical (+99.4%) [15][37]. - The report also details the performance of the Hong Kong and U.S. pharmaceutical sectors, noting that the Hong Kong stock pharmaceutical sector outperformed the market while the U.S. sector underperformed [38]. Market Trends - The report emphasizes the upward trend in the innovative drug market, with traditional pharmaceutical companies emerging from centralized procurement challenges and entering a phase of profitability [36]. - The report indicates that the biopharmaceutical sector's sub-sectors, such as chemical raw materials and biological products, have shown strong performance, with increases of 10.5% and 7.3% respectively [20][37].

Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its 2025 "Quality Improvement and Efficiency Enhancement" action plan, focusing on innovation in drug development and protecting the rights of investors, especially small and medium-sized investors [1][12]. Group 1: Business Strategy and Development - The company aims to accelerate the layout of its core pipeline, focusing on major diseases such as cancer, metabolic disorders, and autoimmune diseases, with a commitment to developing innovative drugs with independent intellectual property rights [1][2]. - The company has two authorized products on the market, one in the registration clinical trial stage, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong position in research and development [2]. - The company plans to advance the clinical research of its D-2570 product, which has shown promising results in Phase II trials for psoriasis, and will explore its potential in other autoimmune diseases [2][3]. Group 2: Research and Development Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens drug development cycles through precise target selection and clinical development processes [2][4]. - The company has a core R&D team with over 20 years of experience in multinational pharmaceutical companies, which strengthens its capabilities in drug design and clinical trial execution [4][5]. - The company has applied for 370 domestic and international invention patents, with 129 granted, ensuring the commercial value of its innovations and reducing potential patent infringement risks [6]. Group 3: Team and Talent Management - The R&D team constitutes over 90% of the company's workforce, with leaders possessing extensive industry experience, which is crucial for the drug development process [7]. - The company plans to implement a new round of equity incentive plans to attract and retain talent, aligning the interests of shareholders and the core team [7]. Group 4: Financial Management and Fund Utilization - The company is focused on improving the efficiency of its fundraising projects and has made adjustments to its headquarters construction project to better meet R&D needs [8]. - In 2025, the company will increase investment in new drug R&D projects, aiming to enhance the efficiency of clinical trials and expand its clinical pipeline [8]. Group 5: Corporate Governance and Compliance - The company is revising its governance structure, including the cancellation of the supervisory board and the enhancement of the board's responsibilities to improve oversight and protect investor rights [9][17]. - The company emphasizes the importance of internal controls and compliance with relevant laws and regulations to ensure effective management of significant matters [9]. Group 6: Information Disclosure and Investor Relations - The company is committed to enhancing the quality of information disclosure and actively engages with investors through various communication channels [10][11]. - The company plans to conduct at least three performance briefings annually to maintain transparency and keep investors informed about its operations and financial status [11].

5月份，格力电器和江苏银行均获得6家券商推荐，当月股价分别上涨4.11%、8.07%；海大集团获得5家 券商推荐，当月股价上涨9.25%。 券商金股组合指数的表现也能反映出券商研究所的业务实力。5月份，有26只券商金股组合指数实现上 涨，其中14只券商金股组合指数当月涨超3%。"国元证券金股指数"当月上涨11.91%，涨幅居首；"国盛 证券金股指数""华创证券金股指数""浙商证券金股指数"当月分别上涨5.29%、4.8%、4.63%。 本报记者 周尚伃 见习记者 于宏 近日，券商密集发布6月份金股名单。截至6月2日，券商已合计推荐132只金股，其中，亚钾国际被推荐 次数暂居第一，已获得4家券商推荐。从行业分布来看，上述132只金股中，来自工业和信息技术行业 （Wind一级行业，下同）的金股数量较多。展望6月份市场行情，多位券商分析师预计，科技、消费板 块仍为投资主线。 5月份最强金股涨超45% 回顾5月份，券商5月份合计推荐的272只金股中，132只金股当月股价实现上涨，占比48.53%。32只金 股当月股价涨幅超10%，占比11.76%。 具体来看，5月份涨幅最高的金股为天风证券推荐的潮宏基，当月涨幅为45 ...

Group 1: Shihua Technology - Shihua Technology is projected to achieve revenue of 795 million yuan and net profit of 280 million yuan in 2024, representing year-on-year growth of 55.36% and 44.56% respectively [1] - In Q1 2025, the company expects revenue of 256 million yuan and net profit of 87 million yuan, with year-on-year growth of 92.04% and 111.23% respectively [1] - The company is deepening its industrial chain layout with multiple projects progressing smoothly, including functional materials expansion and upgrade projects, innovation center projects, and new high-efficiency sealing adhesive projects [1] - A refinancing plan has been disclosed to invest 740 million yuan in optical display film material expansion, with a fundraising target of no more than 600 million yuan, and has received acceptance notification from the Shanghai Stock Exchange [1] - The company has two optical-grade production lines for high-performance optical materials R&D, sampling, and mass production, and is advancing expansion projects due to limited capacity [1] - The market for optical materials is large, with high-end optical materials still dominated by foreign companies, indicating significant domestic substitution potential [1] - Functional materials are applied across multiple product lines for Client A, with varying project sizes and substantial total demand space [1] - The Zhangjiagang factory is producing adhesive products, with ongoing production line debugging and trial production for various fields [1] - The company is closely monitoring the development of foldable screen technology and actively investing in related material R&D [1] - The business primarily focuses on domestic sales, with low export revenue proportion, making it less susceptible to short-term tariff policy changes [1] - The future product structure will consist of high-performance optical materials, functional electronic materials, and functional adhesives, with the fastest growth expected in high-performance optical materials [1] Group 2: Yifang Bio - Yifang Bio has introduced the latest R&D progress of its main products, including D-2570, which plans to conduct clinical exploration in multiple autoimmune disease areas, with the II phase clinical trial for ulcerative colitis approved by CDE and expected to complete the first patient dosing by May 2025 [2] - The drug Gesorex (D-1553) is expected to be approved for market launch in November 2024 for treating adult patients with KRS G12C mutation advanced non-small cell lung cancer, with ongoing phase III clinical research [2] - D-0502 is currently undergoing phase III clinical trials for second-line treatment in China, while also conducting international multi-center clinical trials in both China and the United States [2] - D-0120 has completed phase IIb clinical trials for hyperuricemia and gout, while YF087 and YF550 have made breakthrough progress in preclinical research [2]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.24 CNY, reflecting a reasonable market value of 163.33 billion CNY [2][6]. Core Insights - The company has narrowed its losses, with a notable performance in commercialization expected. The 2024 revenue is projected at 1.69 billion CNY, a decrease of 9.0% year-on-year, while the net loss attributable to the parent company is expected to be 2.40 billion CNY, a reduction of 15.4% year-on-year [9]. - The approval of the drug Gexosrese for commercialization is anticipated to drive growth, with 2025 being the first full year of commercialization for Gexosrese, alongside the inclusion of another drug in the National Medical Insurance Directory [9]. - The clinical pipeline is progressing well, with positive data from the TYK2 inhibitor trials, indicating a strong potential for future revenue generation [9]. Financial Forecasts - Revenue projections for 2025-2027 are as follows: 141 million CNY in 2025, 323 million CNY in 2026, and 525 million CNY in 2027, with respective growth rates of -16.5%, 129.3%, and 62.6% [4]. - The net profit attributable to the parent company is forecasted to be -346 million CNY in 2025, -377 million CNY in 2026, and -290 million CNY in 2027, reflecting a trend of narrowing losses [4]. - The gross margin is expected to remain high, with projections of 100.0% in 2025, 98.9% in 2026, and 98.0% in 2027 [4]. Valuation Metrics - The report provides a detailed valuation analysis, indicating an enterprise value of 14.65 billion CNY and an equity value of 16.33 billion CNY, leading to a per-share value of 28.24 CNY [10]. - The report also includes a sensitivity analysis for the target price based on varying perpetual growth rates and WACC [10].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 28.24 CNY, reflecting a reasonable market value of 163.33 billion CNY [2][6]. Core Insights - The company has shown a narrowing of losses, with a reported revenue of 1.69 billion CNY in 2024, a decrease of 9.0% year-on-year, and a net loss of 240 million CNY, which is a reduction of 15.4% compared to the previous year [9]. - The approval of the drug Gexosrayse for commercialization is expected to enhance revenue streams, with 2025 being the first full year of commercialization for this product [9]. - The clinical pipeline is progressing well, with positive data from the TYK2 inhibitor trials, indicating strong potential for future growth [9]. Financial Forecasts - Revenue projections for 2025-2027 have been adjusted downwards, with expected net profits of -346 million CNY, -377 million CNY, and -290 million CNY respectively [2]. - The company is expected to achieve a significant revenue increase in 2026 and 2027, with growth rates of 129.3% and 62.6% respectively [4]. - The gross margin is projected to remain high, around 100% in 2025, while the net margin is expected to improve significantly by 2027 [4]. Financial Metrics - The company reported a net profit margin of -153.1% in 2023, which is expected to improve to -55.1% by 2027 [4]. - The earnings per share (EPS) is projected to be -0.60 CNY in 2025, improving to -0.50 CNY by 2027 [4]. - The price-to-earnings (P/E) ratio is forecasted to be -40.6 in 2025, indicating the company's current valuation relative to its earnings [4].

General Information - InventisBio Co., Limited is established as a joint-stock company based on the transformation of InventisBio (Shanghai) Co., Ltd, registered in Shanghai with a unified social credit code of 913101150609007219 [3][4] - The company was approved by the Shanghai Stock Exchange on January 20, 2022, and publicly issued 115 million shares of ordinary stock in April 2022, subsequently listing on the Sci-Tech Innovation Board on July 25, 2022 [3][4] Company Structure - The registered capital of the company is RMB 578.327844 million [4] - The company is a permanent joint-stock company, with the chairman serving as the legal representative [4][5] - The company’s assets are divided into equal shares, and shareholders are liable for the company’s debts only to the extent of their subscribed shares [4][5] Governance and Management - The company’s articles of association serve as a legally binding document governing the organization and behavior of the company, shareholders, directors, and senior management [5] - Senior management includes the general manager, deputy general managers, board secretary, financial officer, and other personnel as specified in the articles [5] - The company is required to establish a Communist Party organization and conduct activities in accordance with the Party's regulations [5][6] Business Objectives and Scope - The company aims to adopt advanced technology, production equipment, and scientific management methods to expand international markets and enhance economic benefits [6] - The business scope includes drug production, wholesale, retail, and import/export, along with various biotechnology and pharmaceutical technology services [6][7] Share Issuance and Capital Management - The company issues shares in the form of stocks, with each share having a par value of RMB 1 [7][9] - The total number of shares issued by the company is 578.327844 million, all of which are ordinary shares [9] - The company can increase capital through various means, including issuing shares to unspecified objects, subject to shareholder approval [10][11] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, participate in shareholder meetings, supervise company operations, and transfer their shares [15][16] - Shareholders holding more than 5% of shares must report any pledges of their shares to the company [21][22] - The company’s articles stipulate that shareholders must comply with laws and the articles, and they cannot withdraw their capital except as legally permitted [21][22]

Core Viewpoint - The company is committed to enhancing operational efficiency and management quality through its "Quality Improvement and Efficiency Enhancement" action plan for 2025, aiming to strengthen its core competitiveness and market image while protecting the rights of investors, especially small and medium-sized investors [1] Group 1: Business Strategy and Development - The company focuses on innovative drug research and development in major disease areas such as oncology, metabolism, and autoimmune diseases, aiming to address unmet clinical needs with globally competitive products [1][3] - The company has two authorized products on the market, one in the registration clinical trial phase, two in Phase II clinical trials, and multiple preclinical projects, indicating a strong R&D pipeline [2] - The company plans to expand the clinical exploration of its D-2570 product in multiple autoimmune disease treatment areas, with a Phase II clinical trial for ulcerative colitis approved in March 2025 [2] Group 2: R&D Capabilities - The company has established a comprehensive R&D system that enhances the success rate of its products and shortens the drug development cycle through precise target screening and clinical development [2][4] - The company has a strong R&D team with over 90% of its workforce dedicated to research, and the team leaders possess extensive experience in multinational pharmaceutical companies [5][6] - The company has applied for 370 domestic and international invention patents, with 129 granted, emphasizing its commitment to innovation and intellectual property protection [5] Group 3: Governance and Investor Relations - The company is enhancing its governance structure by clarifying the responsibilities of the board and independent directors to protect the rights of minority investors [7] - The company prioritizes high-quality information disclosure and investor communication, utilizing various channels to keep investors informed about its operations and financial status [8][9] - The company plans to implement a new round of equity incentive plans to align the interests of shareholders and the core team, fostering long-term development [6] Group 4: Funding and Investment Efficiency - The company is optimizing its fundraising projects to enhance the efficiency of its R&D investments, including the integration and upgrade of its existing R&D and operational facilities [6] - The investment in key projects will support the clinical trial processes and the exploration of new indications, thereby strengthening the company's competitive edge in innovative drug development [6]

Summary of Key Points Core Viewpoint The announcement details the changes in the governance structure of Yifang Biotechnology (Shanghai) Co., Ltd., including the cancellation of the supervisory board, changes in registered capital, and amendments to the company's articles of association and internal governance systems. Group 1: Changes in Registered Capital - The total share capital of the company increased to RMB 578,327,844 following the completion of the stock registration for the second vesting period of the restricted stock incentive plan on March 24, 2025 [1][2] - The board of directors authorized relevant personnel to handle the business registration changes without needing to submit the matter to the shareholders' meeting [2] Group 2: Cancellation of Supervisory Board - The company will no longer have a supervisory board, and its functions will be transferred to the audit committee of the board of directors [2][3] - Relevant internal rules related to the supervisory board will be abolished [2] Group 3: Amendments to Articles of Association and Governance Systems - The articles of association will be revised to align with the current laws and regulations, including the Company Law and the Guidelines for Articles of Association of Listed Companies [2][4] - Internal governance systems, including rules for shareholders' meetings, board meetings, and various committees, will be amended, with some requiring approval from the shareholders' meeting [2][3]

Group 1 - The company, Yifang Biotechnology (Shanghai) Co., Ltd., is set to hold its 2024 Annual General Meeting on June 20, 2025, at 9:30 AM in Shanghai [1][3] - Voting will be conducted through a combination of on-site and online methods, utilizing the Shanghai Stock Exchange's network voting system [1][4] - The registration date for shareholders to attend the meeting is June 13, 2025, and registration will be open from June 18, 2025 [5][6] Group 2 - The meeting will review several non-cumulative voting proposals, including the "Independent Director Work System" and "Related Party Transaction Management System" [3][4] - Shareholders must complete voting for all proposals before submission, and any duplicate votes will be counted as the first vote [4][6] - Shareholders attending the meeting must bring identification and proof of shareholding, and transportation and accommodation costs will be borne by the attendees [6][7]